Valneva Austria Gmbh

Intercell Ag

Thomas Cipps

Andreas Meinke

Eszter Nagy

Urban Lundberg

Markus Hanner

Alexander Von Gabain

Ulrike Stierschneider

Birgit Noiges

Jutta Pikalo

Christina Satke

Dagmar Zierer

Sharmila Bakshi

The present invention relates to an isolated nucleic acid molecule encoding an antigen, a vector comprising such nucleic acid molecule and a host cell comprising such vector. Furthermore, the invention provides antigens fromspecies, fragments and variants thereof, a process for producing such antigens, and a process for producing cells expressing such antigens. Moreover, the present invention provides antibodies binding to such antigen, hybridoma cells producing such antibodies, methods for producing such antibodies, a pharmaceutical composition comprising such nucleic acid molecule, antigen, vector or antibody, the use of such nucleic acid molecule, antigen, vector or antibody for the preparation of a pharmaceutical composition, methods for identifying an antagonist capable of binding such antigen or of inhibiting the interaction activity of such antigen, methods for diagnosis or for treatment or prevention of an infection. More specifically, such antigens are associated with nosocomial bacterial infections or infection by

[object Object]

The present invention relates to isolated nucleic acid molecules which encode an antigen, a vector which comprises such nucleic acid molecule, and a host cell comprising such vector. Furthermore, the invention provides antigens from aspecies, as well as fragments and variants thereof, a process for producing such antigens, and a process for producing a cell, which expresses such antigen. Moreover, the present invention provides antibodies binding to such antigen, a hybridoma cell producing such antibodies, methods for producing such antibodies, a pharmaceutical composition comprising such nucleic acid molecule, antigen, vector or antibody, the use of such nucleic acid molecule, antigen, vector or antibody for the preparation of a pharmaceutical composition, methods for identifying an antagonist capable of binding such antigen or of reducing or inhibiting the interaction activity of such antigen, methods for diagnosing an infection and methods for the treatment or prevention of an infection. More specifically such antigens are produced by or associated with bacterial pathogens causing nosocomial infections or bacterial infections caused by

Growing community of inventors

Vienna, Austria

Thomas Cipps